Smartleaf Asset Management’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.9K Buy
463
+111
+32% +$2.81K ﹤0.01% 2358
2026
Q2
$8.83K Hold
352
– – ﹤0.01% 2417
2026
Q1
$8.19K Sell
352
-410
-54% -$9.11K ﹤0.01% 2422
2025
Q4
$19.9K Buy
762
+183
+32% +$4.35K ﹤0.01% 2038
2025
Q3
$14.7K Buy
579
+410
+243% +$10.1K ﹤0.01% 1948
2025
Q2
$3.97K Sell
169
-249
-60% -$6.28K ﹤0.01% 2122
2025
Q1
$10.4K Sell
418
-7
-2% -$168 ﹤0.01% 1914
2024
Q4
$8.05K Buy
425
+394
+1,271% +$6.92K ﹤0.01% 2077
2024
Q3
$450 Sell
31
-236
-88% -$4.04K ﹤0.01% 2791
2024
Q2
$7.45K Buy
+267
New +$7.6K ﹤0.01% 1577

Other funds holding PCRX

Smartleaf Asset Management's PCRX Position: Q3 2026 in Review

Smartleaf Asset Management increased its Pacira BioSciences (PCRX) stake by 32% in Q3 2026, buying an estimated $2.81K and bringing the position to 463 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2358.

Smartleaf Asset Management first reported a position in PCRX in Q2 2024 and has held it in 10 quarters since. The position peaked at $19.9K in Q4 2025. 258 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

  • Smartleaf Asset Management held 463 shares of Pacira BioSciences worth $11.9K as of Q3 2026.
  • Smartleaf Asset Management bought 111 Pacira BioSciences shares in Q3 2026, an estimated $2.81K.
  • Pacira BioSciences made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #2358 holding.
  • Smartleaf Asset Management first reported a position in Pacira BioSciences in Q2 2024 and has held it in 10 quarters since.
  • Smartleaf Asset Management's Pacira BioSciences position peaked at $19.9K in Q4 2025.
  • 258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.